Alla E. Lavrova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alla E. Lavrova has a total of 267 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Yu. Konovalova
Privolzhsky Research Medical University
9 shared publications - Anna Yu. Voronkova
Research Centre for Medical Genetics
4 shared publications - Marina V. Presnyakova
Privolzhsky Research Medical University
4 shared publications - Vera V. Shadrina
Research Clinical Institute of Childhood
4 shared publications - Aleksandr Aleksandrovich Baranov
Russian Scientific Center of Surgery named after B. V. Petrovsky; I. M. Sechenov First Moscow State Medical University (Sechenov University)
3 shared publications - Elena L. Amelina
Laboratory of Cystic Fibrosis, Research Institute of Pulmonology, 11th Parkovaya Str., 32/4, 105077 Moscow, Russia
3 shared publications
Latest Publications
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Dynamics of lung function in patients with cystic fibrosis living in the Volga Federal District in 2017 and 2023
Cystic fibrosis (CF) is a severe hereditary disease that leads to decreased lung function. Objective. To assess the dynamics of lung function changes in CF patients living in the Volga Federal District (VFD) regions based on data from the 2017 and 2023 registries. Material and methods. Spirometry data from 375 patients from the 2017 CF patient registry and 451 patients from the 2023 registry were analyzed. Results. The median FEV1 data in VFD patients was 76.8% of the predicted value in 2017 and significantly increased to 95.3% of the predicted value in 2018. in 2023 (p<0.001). In 2017, FEV1 values in patients with CF in the Volga Federal District were not significantly different from those in the Russian Federation (75.5% of the predicted value), while in 2023, they were significantly higher than in patients in other regions of Russia (81.1% of the predicted value), p<0.001. FEV1 values increased significantly in patients from the Nizhny Novgorod Region, Orenburg Region, Perm Krai, the Republic of Tatarstan, and the Chuvash Republic. The median FVC in patients with CF from the Volga Federal District in 2017 was 85.1% of the predicted value and significantly increased to 94.0% of the predicted value in 2023 (p<0.01). In 2017, the FVC indicators in patients with CF in the Volga Federal District did not differ significantly from those in patients in the Russian Federation (86.0% of the predicted value), and in 2023 they were significantly higher than in patients in other regions of Russia (91.0% of the predicted value), p=0.037. The FVC indicators in 2023, compared with 2017, significantly increased in patients in the Nizhny Novgorod Region (p<0.001), Orenburg Region (p<0.001), Perm Krai (p=0.021), the Republic of Tatarstan (p=0.043), and the Chuvash Republic (p=0.003). In patients in the Samara Region, the indicators remained stable (p=0.331). Conclusions. FEV1 and FVC values in CF patients in both the Volga Federal District and the Russian Federation increased significantly in 2023 compared to 2017. Patient data from Volga Federal District regions where specialized CF centers were established were more informative, and patients had higher lung function values.
- 14 October 2026
- Published by Media Sphere Publishing Group in Journal of Respiratory Medicine
- Vol. 2 (3)
Dynamics of lung function in patients with cystic fibrosis living in the Volga Federal District in 2017 and 2023
Cystic fibrosis (CF) is a severe hereditary disease that leads to decreased lung function. Objective. To assess the dynamics of lung function changes in CF patients living in the Volga Federal District (VFD) regions based on data from the 2017 and 2023 registries. Material and methods. Spirometry data from 375 patients from the 2017 CF patient registry and 451 patients from the 2023 registry were analyzed. Results. The median FEV1 data in VFD patients was 76.8% of the predicted value in 2017 and significantly increased to 95.3% of the predicted value in 2018. in 2023 (p<0.001). In 2017, FEV1 values in patients with CF in the Volga Federal District were not significantly different from those in the Russian Federation (75.5% of the predicted value), while in 2023, they were significantly higher than in patients in other regions of Russia (81.1% of the predicted value), p<0.001. FEV1 values increased significantly in patients from the Nizhny Novgorod Region, Orenburg Region, Perm Krai, the Republic of Tatarstan, and the Chuvash Republic. The median FVC in patients with CF from the Volga Federal District in 2017 was 85.1% of the predicted value and significantly increased to 94.0% of the predicted value in 2023 (p<0.01). In 2017, the FVC indicators in patients with CF in the Volga Federal District did not differ significantly from those in patients in the Russian Federation (86.0% of the predicted value), and in 2023 they were significantly higher than in patients in other regions of Russia (91.0% of the predicted value), p=0.037. The FVC indicators in 2023, compared with 2017, significantly increased in patients in the Nizhny Novgorod Region (p<0.001), Orenburg Region (p<0.001), Perm Krai (p=0.021), the Republic of Tatarstan (p=0.043), and the Chuvash Republic (p=0.003). In patients in the Samara Region, the indicators remained stable (p=0.331). Conclusions. FEV1 and FVC values in CF patients in both the Volga Federal District and the Russian Federation increased significantly in 2023 compared to 2017. Patient data from Volga Federal District regions where specialized CF centers were established were more informative, and patients had higher lung function values.
- 9 October 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (5)
RESULTS OF A PROSPECTIVE MULTICENTER OPEN-LABEL OBSERVATIONAL STUDY OF ENZYME REPLACEMENT THERAPY WITH AN IMIGLUCERASE BIOSIMILAR IN CHILDREN WITH TYPE 1 GAUCHER DISEASE
Enzyme replacement therapy (ERT) is the mainstay for type 1 Gaucher disease (GD1) treatment. Imiglucerase biosimilar usage allows to control GD1 manifestations and improve the patients’ life quality according to interventional clinical studies. Objective: To evaluate the results of Glurazyme® use during long-term ERT in patients younger than 18 years with GD1 within a prospective multicenter observational study. Materials and methods: A total of 7 children aged 8–16 years with GD1 who receive ERT with Glurazim® were selected to participate in this prospective multicenter, non-comparative observational study. The study included a screening period (28 days) and a treatment period (52 weeks). Efficacy was assessed based on the hemoglobin dynamics over the observation period. Additionally, changes in platelet count, spleen and liver volumes, bone tissue condition, and the need for dose adjustments were studied. All reported adverse events (AE) were analyzed to assess treatment safety. Results: The average duration of the study for one patient was 363 [354.5; 376] days. The median values of a Glurazim® single dose were 1400 [900; 1900] U. During the study, two patients (28.6%) required a drug dose increase due to children growth. Hemoglobin and platelet concentrations remained stable, no significant changes were registered (p=0.32 and p=0.85, respectively). No increase in the spleen or liver volume was observed: p=0.78 and p=0.37, respectively. There were no new cases of aseptic bone necrosis during the study. All AEs were not related to the study drug. Conclusion: In this group of children with GD1, one year of Glurazyme® therapy was associated with stable hematological, visceral, and bone parameters, with no drug-related AEs observed. These findings support the evidence that long-term treatment with the imiglucerase biosimilar is effective in achieving therapeutic goals in pediatric patients with Gaucher disease.
- 9 October 2026
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 105 (5)
RESULTS OF A PROSPECTIVE MULTICENTER OPEN-LABEL OBSERVATIONAL STUDY OF ENZYME REPLACEMENT THERAPY WITH AN IMIGLUCERASE BIOSIMILAR IN CHILDREN WITH TYPE 1 GAUCHER DISEASE
Enzyme replacement therapy (ERT) is the mainstay for type 1 Gaucher disease (GD1) treatment. Imiglucerase biosimilar usage allows to control GD1 manifestations and improve the patients’ life quality according to interventional clinical studies. Objective: To evaluate the results of Glurazyme® use during long-term ERT in patients younger than 18 years with GD1 within a prospective multicenter observational study. Materials and methods: A total of 7 children aged 8–16 years with GD1 who receive ERT with Glurazim® were selected to participate in this prospective multicenter, non-comparative observational study. The study included a screening period (28 days) and a treatment period (52 weeks). Efficacy was assessed based on the hemoglobin dynamics over the observation period. Additionally, changes in platelet count, spleen and liver volumes, bone tissue condition, and the need for dose adjustments were studied. All reported adverse events (AE) were analyzed to assess treatment safety. Results: The average duration of the study for one patient was 363 [354.5; 376] days. The median values of a Glurazim® single dose were 1400 [900; 1900] U. During the study, two patients (28.6%) required a drug dose increase due to children growth. Hemoglobin and platelet concentrations remained stable, no significant changes were registered (p=0.32 and p=0.85, respectively). No increase in the spleen or liver volume was observed: p=0.78 and p=0.37, respectively. There were no new cases of aseptic bone necrosis during the study. All AEs were not related to the study drug. Conclusion: In this group of children with GD1, one year of Glurazyme® therapy was associated with stable hematological, visceral, and bone parameters, with no drug-related AEs observed. These findings support the evidence that long-term treatment with the imiglucerase biosimilar is effective in achieving therapeutic goals in pediatric patients with Gaucher disease.
- 28 February 2025
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 104 (1)
"Recent developments in the nutrition of children with cystic fibrosis," Resolution by the Expert Council dated December 12, 2024, Moscow, Russia
T.E. Borovik, O.I. Simonova, S.V. Voronin, T.V. Bushuyeva, Ina Sokolov, A.A. Pashkevich, A.E. Lavrova, N.A. Ilyenkova, D.F. Sergiyenko, A.A. Agafonova, N.Yu. Filina, I.P. Karimova. "Recent developments in the nutrition of children with cystic fibrosis," Resolution by the Expert Council dated December 12, 2024, Moscow, Russia. Pediatria n.a. G.N. Speransky. 2025; 104 (1): 151-154. DOI: 10.24110/0031-403X-2025-104-1-151-154.
- 28 February 2025
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 104 (1)
"Recent developments in the nutrition of children with cystic fibrosis," Resolution by the Expert Council dated December 12, 2024, Moscow, Russia
T.E. Borovik, O.I. Simonova, S.V. Voronin, T.V. Bushuyeva, Ina Sokolov, A.A. Pashkevich, A.E. Lavrova, N.A. Ilyenkova, D.F. Sergiyenko, A.A. Agafonova, N.Yu. Filina, I.P. Karimova. "Recent developments in the nutrition of children with cystic fibrosis," Resolution by the Expert Council dated December 12, 2024, Moscow, Russia. Pediatria n.a. G.N. Speransky. 2025; 104 (1): 151-154. DOI: 10.24110/0031-403X-2025-104-1-151-154.
- Open Access
- 26 December 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (6) , 551-568
Modern Clinical Guidelines for the Management of Patients with Gaucher Disease
This article presents data on the epidemiology, pathogenesis, modern classification and the main clinical manifestations of Gaucher disease in children. The criteria for differential diagnosis with other diseases are given. It has been shown that the only effective method of treating Gaucher disease is pathogenetic enzyme replacement therapy, which relieves the main clinical manifestations of the disease, improving the quality of life of patients and without having pronounced side effects. The main errors of diagnosis and management of patients, as well as unjustified prescriptions for the treatment of this disease, are indicated.
- 26 December 2024
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 21 (6) , 551-568
Open AccessModern Clinical Guidelines for the Management of Patients with Gaucher Disease
This article presents data on the epidemiology, pathogenesis, modern classification and the main clinical manifestations of Gaucher disease in children. The criteria for differential diagnosis with other diseases are given. It has been shown that the only effective method of treating Gaucher disease is pathogenetic enzyme replacement therapy, which relieves the main clinical manifestations of the disease, improving the quality of life of patients and without having pronounced side effects. The main errors of diagnosis and management of patients, as well as unjustified prescriptions for the treatment of this disease, are indicated.
- 9 August 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (4)
Clinical and genetic characteristics of pediatric patients with suspected hereditary liver diseases: an algorithm for differential diagnosis
Hepatitides of unspecified etiology in children may be caused by genetic disorders. Its early detection can improve the patient management with understanding the pathogenesis, more accurately predicting the course, preventive examinations and prescribing specialized pathogenetic therapy in selected cases. However, currently there are no guidelines for the optimal diagnosis of such cases. The purpose of this research was to develop an algorithm for the differential diagnosis of hepatitides of unspecified etiology in children based on the identified clinical and genetic features of hereditary liver diseases. Materials and methods used: a single-center cohort retrospective study of 179 children with hepatitides of unspecified etiology aged 0 to 18 y/o was conducted. All patients had undergone genetic examination, based on the results of which the two groups were formed as follows: with and without genetic liver disease. Statistical analysis of the patients’ clinical, laboratory and instrumental examinations was aimed at identifying key markers for common hereditary liver diseases in different age groups as well as statistically significant differences in rare genetic reasons for hepatitis. Results: 27 different genetic liver diseases were identified in 101 (56.4%) with hepatitis of unspecified etiology. The most frequently detected diseases were Wilson's disease (41 or 40.6%), alpha-1 antitrypsin deficiency (A1AD or AATD) (9 or 8.9%) and Alagille syndrome (ALGS) (8 or 7.9%). Other hereditary pathologies occurred in isolated cases though its total incidence was nearly half of all cases (43 or 42.6%). In order to identify such cases, it is advisable to perform exome sequencing. In order to determine the indications for genetic examination, Authors have developed the mathematical model for assessing the risk of hereditary liver disease (ROC-AUC 0.787 with 95% CI: 0.696-0.877, sensitivity 69.8% with 95% CI: 57.7%-81.3%, specificity 79.2% with 95% CI: 72.3%-84.8%). Conclusion: Authors offer the suggested algorithm for differential diagnosis of hepatitides of unspecified etiology in children that includes, on the first place, the exclusion of the most common genetic liver diseases followed by exome sequencing in high-risk cases that in its turn is calculated using the developed mathematical model.
- 9 August 2024
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 103 (4)
Clinical and genetic characteristics of pediatric patients with suspected hereditary liver diseases: an algorithm for differential diagnosis
Hepatitides of unspecified etiology in children may be caused by genetic disorders. Its early detection can improve the patient management with understanding the pathogenesis, more accurately predicting the course, preventive examinations and prescribing specialized pathogenetic therapy in selected cases. However, currently there are no guidelines for the optimal diagnosis of such cases. The purpose of this research was to develop an algorithm for the differential diagnosis of hepatitides of unspecified etiology in children based on the identified clinical and genetic features of hereditary liver diseases. Materials and methods used: a single-center cohort retrospective study of 179 children with hepatitides of unspecified etiology aged 0 to 18 y/o was conducted. All patients had undergone genetic examination, based on the results of which the two groups were formed as follows: with and without genetic liver disease. Statistical analysis of the patients’ clinical, laboratory and instrumental examinations was aimed at identifying key markers for common hereditary liver diseases in different age groups as well as statistically significant differences in rare genetic reasons for hepatitis. Results: 27 different genetic liver diseases were identified in 101 (56.4%) with hepatitis of unspecified etiology. The most frequently detected diseases were Wilson's disease (41 or 40.6%), alpha-1 antitrypsin deficiency (A1AD or AATD) (9 or 8.9%) and Alagille syndrome (ALGS) (8 or 7.9%). Other hereditary pathologies occurred in isolated cases though its total incidence was nearly half of all cases (43 or 42.6%). In order to identify such cases, it is advisable to perform exome sequencing. In order to determine the indications for genetic examination, Authors have developed the mathematical model for assessing the risk of hereditary liver disease (ROC-AUC 0.787 with 95% CI: 0.696-0.877, sensitivity 69.8% with 95% CI: 57.7%-81.3%, specificity 79.2% with 95% CI: 72.3%-84.8%). Conclusion: Authors offer the suggested algorithm for differential diagnosis of hepatitides of unspecified etiology in children that includes, on the first place, the exclusion of the most common genetic liver diseases followed by exome sequencing in high-risk cases that in its turn is calculated using the developed mathematical model.
- Open Access
- 5 May 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (2) , 104-110
Wilson’s Disease Caused by Previously Undescribed Homozygous Nucleotide Variant of the ATP7B Gene: Clinical Cases
Wilson’s disease is severe autosomal recessive disease manifested primarily by hepatic, neurological, and psychiatric disorders due to excessive copper deposition in organs and tissues. Clinical case description. The variant with uncertain clinical value of the ATP7B gene, c.2111C>T (p.T704I, chr13:52534294G>A (HG19)), was described in the family where parents are cousins. The eldest daughter out of four children died at the age of 11 due to liver cirrhosis. Wilson’s disease was genetically confirmed in two children (clinically — abdominal form). The younger son was diagnosed heterozygous state of the disease (without any clinical manifestations). The revealed variant of the ATP7B gene was previously identified in 3 more patients with Wilson’s disease, however, in a compound heterozygous state with known pathogenic genetic variant. Conclusion. c.2111C>T (p.T704I) variant of the ATP7B gene can be considered as probably pathogenic. Further research is required to evaluate its functional significance in Wilson’s disease pathogenesis.
- 5 May 2024
- Published by Paediatrician Publishers LLC in Current Pediatrics
- Vol. 23 (2) , 104-110
Open AccessWilson’s Disease Caused by Previously Undescribed Homozygous Nucleotide Variant of the ATP7B Gene: Clinical Cases
Wilson’s disease is severe autosomal recessive disease manifested primarily by hepatic, neurological, and psychiatric disorders due to excessive copper deposition in organs and tissues. Clinical case description. The variant with uncertain clinical value of the ATP7B gene, c.2111C>T (p.T704I, chr13:52534294G>A (HG19)), was described in the family where parents are cousins. The eldest daughter out of four children died at the age of 11 due to liver cirrhosis. Wilson’s disease was genetically confirmed in two children (clinically — abdominal form). The younger son was diagnosed heterozygous state of the disease (without any clinical manifestations). The revealed variant of the ATP7B gene was previously identified in 3 more patients with Wilson’s disease, however, in a compound heterozygous state with known pathogenic genetic variant. Conclusion. c.2111C>T (p.T704I) variant of the ATP7B gene can be considered as probably pathogenic. Further research is required to evaluate its functional significance in Wilson’s disease pathogenesis.
- Open Access
- 11 March 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (2) , 206-217
Results of a prospective open observational study of the use of dornase alfa as part of complex therapy for patients with cystic fibrosis
The article discusses results of a prospective observational study of long-term use of the biosimilar dornase alfa (Tigerase) (Generium, Russia) as part of complex therapy in patients with cystic fibrosis in real clinical practice.The aim was to analyze the outcomes of long-term use of the dornase alfa dornase alfa as part of complex therapy in patients with CF (protocol #DRN-CFR-N01).Methods. The study included patients (n = 165) aged 5 years and older from 11 centers for treatment of cystic fibrosis in the Russian Federation with a confirmed diagnosis of cystic fibrosis who were prescribed dornase alfa by their attending physician.Results. The analysis revealed that exacerbations of chronic pulmonary disease during the treatment with dornase alfa were observed in 29 (17.58%) patients included in the study. At the same time, there were no statistically significant changes in FEV1 and FVC (%) against baseline during the treatment in the study population. Adverse events related to the study drug were recorded in 9 (5.45%) patients.Conclusion. Biosimilar dornase alfa demonstrated a favorable efficacy and safety profile in routine clinical practice, which confirms the results of previously published studies.
- 11 March 2024
- Published by Scientific and Practical Reviewed Journal Pulmonology in PULMONOLOGIYA
- Vol. 34 (2) , 206-217
Open AccessResults of a prospective open observational study of the use of dornase alfa as part of complex therapy for patients with cystic fibrosis
The article discusses results of a prospective observational study of long-term use of the biosimilar dornase alfa (Tigerase) (Generium, Russia) as part of complex therapy in patients with cystic fibrosis in real clinical practice.The aim was to analyze the outcomes of long-term use of the dornase alfa dornase alfa as part of complex therapy in patients with CF (protocol #DRN-CFR-N01).Methods. The study included patients (n = 165) aged 5 years and older from 11 centers for treatment of cystic fibrosis in the Russian Federation with a confirmed diagnosis of cystic fibrosis who were prescribed dornase alfa by their attending physician.Results. The analysis revealed that exacerbations of chronic pulmonary disease during the treatment with dornase alfa were observed in 29 (17.58%) patients included in the study. At the same time, there were no statistically significant changes in FEV1 and FVC (%) against baseline during the treatment in the study population. Adverse events related to the study drug were recorded in 9 (5.45%) patients.Conclusion. Biosimilar dornase alfa demonstrated a favorable efficacy and safety profile in routine clinical practice, which confirms the results of previously published studies.
- 15 December 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (6)
Guidelines for Practitioners: Duchenne Muscular Dystrophy (DMD). Becker Muscular Dystrophy (BMD). Early diagnosis. Therapy with the use of drugs that are currently not registered properly in Russia/by the Ministry of Healthcare of Russia
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.
- 15 December 2023
- Published by Pediatria, Ltd. in Pediatria. Journal named after G.N. Speransky
- Vol. 102 (6)
Guidelines for Practitioners: Duchenne Muscular Dystrophy (DMD). Becker Muscular Dystrophy (BMD). Early diagnosis. Therapy with the use of drugs that are currently not registered properly in Russia/by the Ministry of Healthcare of Russia
Вам открыли доступ к файлу. Отправлено с помощью Облако Mail.ru.
- Open Access
- 22 August 2023
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 20 (4) , 337-354
Clinical guidelines for the management of children with lysosomal acid lipase deficiency
Lysosomal acid lipase deficiency is s a rare hereditary enzymopathy. The article presents epidemiological data and features of etiopathogenesis of two phenotypic forms of lysosomal acid lipase deficiency — Wolman disease and cholesterol ester storage disease. Special attention has been given to the key issues of differential diagnostic search, clinical guidelines based on the principles of evidence-based medicine have been given.
- 22 August 2023
- Published by Paediatrician Publishers LLC in Pediatric pharmacology
- Vol. 20 (4) , 337-354
Open AccessClinical guidelines for the management of children with lysosomal acid lipase deficiency
Lysosomal acid lipase deficiency is s a rare hereditary enzymopathy. The article presents epidemiological data and features of etiopathogenesis of two phenotypic forms of lysosomal acid lipase deficiency — Wolman disease and cholesterol ester storage disease. Special attention has been given to the key issues of differential diagnostic search, clinical guidelines based on the principles of evidence-based medicine have been given.